Nothing Special   »   [go: up one dir, main page]

IL107184A - Heterocyclic ether compounds that enhance cognitive function - Google Patents

Heterocyclic ether compounds that enhance cognitive function

Info

Publication number
IL107184A
IL107184A IL10718493A IL10718493A IL107184A IL 107184 A IL107184 A IL 107184A IL 10718493 A IL10718493 A IL 10718493A IL 10718493 A IL10718493 A IL 10718493A IL 107184 A IL107184 A IL 107184A
Authority
IL
Israel
Prior art keywords
ether compounds
heterocyclic ether
cognitive function
enhance cognitive
cholinergic
Prior art date
Application number
IL10718493A
Other languages
English (en)
Other versions
IL107184A0 (en
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of IL107184A0 publication Critical patent/IL107184A0/xx
Publication of IL107184A publication Critical patent/IL107184A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL10718493A 1992-10-09 1993-10-04 Heterocyclic ether compounds that enhance cognitive function IL107184A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95900592A 1992-10-09 1992-10-09

Publications (2)

Publication Number Publication Date
IL107184A0 IL107184A0 (en) 1994-01-25
IL107184A true IL107184A (en) 1997-08-14

Family

ID=25501548

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10718493A IL107184A (en) 1992-10-09 1993-10-04 Heterocyclic ether compounds that enhance cognitive function

Country Status (12)

Country Link
EP (1) EP0663912B1 (xx)
JP (1) JP3098035B2 (xx)
KR (1) KR100311546B1 (xx)
AT (1) ATE210656T1 (xx)
AU (1) AU687017B2 (xx)
CA (1) CA2136075C (xx)
DE (1) DE69331329T2 (xx)
DK (1) DK0663912T3 (xx)
ES (1) ES2169727T3 (xx)
IL (1) IL107184A (xx)
PT (1) PT663912E (xx)
WO (1) WO1994008992A1 (xx)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948793A (en) * 1992-10-09 1999-09-07 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release
US5852041A (en) * 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5998404A (en) * 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5605908A (en) * 1994-10-24 1997-02-25 Eli Lilly And Company Heterocyclic compounds and their use
US5585388A (en) * 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
IL118279A (en) * 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
JP2000500452A (ja) * 1995-11-13 2000-01-18 イーライ・リリー・アンド・カンパニー 不安の処置法
US5794887A (en) 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
US6979695B2 (en) 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
US6437138B1 (en) 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US5629325A (en) * 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
BR9714677A (pt) * 1996-12-10 2000-10-03 Abbott Lab "enantiÈmeros 3-piridila e seu uso como analgésicos"
US6133253A (en) * 1996-12-10 2000-10-17 Abbott Laboratories 3-Pyridyl enantiomers and their use as analgesics
EP0978280A1 (en) * 1997-04-26 2000-02-09 Sumitomo Pharmaceuticals Company, Limited 2-azabicyclo compounds
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6624173B1 (en) 1997-06-30 2003-09-23 Targacept, Inc. Pharmaceutical compositions for treating and/or preventing CNS disorders
US6525065B1 (en) 1997-06-30 2003-02-25 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
CA2306477A1 (en) * 1997-11-05 1999-05-20 Neurosearch A/S Azaring-ether derivatives and their use as nicotinic ach receptor modulators
ATE262519T1 (de) * 1997-12-19 2004-04-15 Abbott Lab Heterozyklische ether- und thioether-verbindungen,verwendbar zur steuerung von chemischer synaptischer transmission
WO1999051216A2 (en) 1998-04-02 1999-10-14 R.J. Reynolds Tobacco Company 3-pyridyloxyalkylamine or aryloxyalkylamine derivatives as cholinergic agonists
CA2317567A1 (en) * 1998-04-02 1999-10-14 R.J. Reynolds Tobacco Company Pharmaceutical compositions and methods for use
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
AU5483500A (en) * 1999-07-09 2001-01-30 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
MXPA02002115A (es) * 1999-09-14 2002-10-31 Abbott Lab Compuestos de eter 3-pirrolidiniloxi-3'-piridilico, utiles para controlar la transmision sinaptica quimica. .
US6890935B2 (en) 1999-11-01 2005-05-10 Targacept, Inc. Pharmaceutical compositions and methods for use
US6812314B2 (en) 2001-10-17 2004-11-02 University Of Florida Thermally responsive polymer materials and uses thereof
BR0214929A (pt) 2001-12-14 2006-05-30 Targacept Inc métodos e composições para o tratamento de distúrbios do sistema nervoso central
ES2355157T3 (es) 2002-07-05 2011-03-23 Targacept, Inc. Compuestos diazaspirocíclico n-arilo y métodos de preparación y uso de las mismas.
AU2003254016A1 (en) 2002-07-19 2004-02-09 Catholic Healthcare West Methods and compositions relating to chimeric nicotinic receptor subunits
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
US7098331B2 (en) 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
ATE451368T1 (de) 2003-10-15 2009-12-15 Targacept Inc Azabicyclische verbindungen zur linderung von schmerzen und zur behandlung von erkrankungen des zentralen nervensystems
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
US7780981B2 (en) 2004-09-13 2010-08-24 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
EP1802601A1 (en) 2004-09-20 2007-07-04 Targacept, Inc. Azaspiroalkene and azapiroalkane compounds with nicotinic cholinergic receptor activity
UA88792C2 (xx) 2004-11-10 2009-11-25 Таргасепт, Інк. Гідроксибензоатні солі метанікотинових сполук$гидроксибензоатные соли метаникотиновых соединений
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
WO2007024814A1 (en) 2005-08-22 2007-03-01 Targacept, Inc. HETEROARYL-SUBSTiTUTED DIAZATRICYCLOALKANES, METHODS FOR ITS PREPARATION AND USE THEREOF
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
EP2133337A1 (en) 2006-05-09 2009-12-16 AstraZeneca AB Salt forms of (2S)-(4E)-N-Methyl-5-[(5-Isopropoxy)pyridin-3-yl]-4-penten-2-amine
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
TWI454262B (zh) 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
KR20090095608A (ko) * 2006-11-29 2009-09-09 바스프 에스이 해충 방제용 피리딘 화합물
US20100028447A1 (en) 2007-01-22 2010-02-04 Targacept, Inc. Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs
TW200845977A (en) 2007-03-30 2008-12-01 Targacept Inc Sub-type selective azabicycloalkane derivatives
KR20110075044A (ko) 2007-04-02 2011-07-05 파킨슨즈 인스티튜트 처치 치료의 부작용을 감소시키기 위한 방법 및 조성물
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
JP5022494B2 (ja) 2007-10-01 2012-09-12 コメンティス，インコーポレーテッド アルツハイマー病治療用のα７ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン−４−イルメチル１Ｈ−インドール−３−カルボキシレート誘導体
JP2012505834A (ja) * 2008-10-14 2012-03-08 サイコジェニックス・インコーポレーテッド ニコチン性アセチルコリン受容体リガンドおよびその使用
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
NZ703381A (en) 2008-12-01 2016-03-31 Targacept Inc Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
TW201024283A (en) 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
MX2012006484A (es) 2009-12-07 2012-08-01 Targacept Inc 3,6-diazabiciclo [3.1.1] heptanos como ligandos de receptores nicotinicos neuronales de acetilcolina.
WO2011146009A1 (en) 2010-05-20 2011-11-24 Targacept Inc. New process for the preparation of aryl substituted olefinic amines
PE20130775A1 (es) 2010-05-27 2013-07-21 Targacept Inc Antagonistas no competitivos de receptores nicotinicos
WO2012125518A1 (en) 2011-03-14 2012-09-20 Targacept, Inc. Salt forms of 3 - cyclopropylcarbonyl - 3, 6 - diazabicyclo [3.1.1] heptane
WO2012129262A1 (en) 2011-03-23 2012-09-27 Targacept, Inc. Treatment of attention deficit/hyperactivity disease
TW201311698A (zh) 2011-08-22 2013-03-16 Targacept Inc 作為神經元菸鹼乙醯膽鹼受體配位體之１，４－二氮雜雙環［３．２．２］壬烷
EP2776030B1 (en) * 2011-11-11 2020-05-13 Georgetown University 2,5-disubstituted-pyridyl nicotinic ligands, and methods of use thereof
EP3166940A4 (en) 2014-07-11 2018-04-25 Alpharmagen, LLC Quinuclidine compounds for modulating alpha7 -nicotinic acetylcholine receptor activity
WO2016123406A1 (en) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Drug delivery methods and systems
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
CN105418477B (zh) * 2015-12-22 2018-12-21 爱斯特（成都）生物制药股份有限公司 降低雷迪帕韦中间体中非对映异构体杂质含量的方法
AU2018205529B2 (en) 2017-01-06 2023-08-10 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
CA3101966A1 (en) 2018-05-29 2019-12-05 Morningside Venture Investments Limited Drug delivery methods and systems

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA848275B (en) * 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
CA1307790C (en) * 1987-08-04 1992-09-22 Ian Anthony Cliffe Ethers
YU84791A (xx) * 1990-05-19 1994-06-10 Boehringer Ingelheim Kg. Biciklični 1-aza-cikloalkalni

Also Published As

Publication number Publication date
AU5355794A (en) 1994-05-09
DK0663912T3 (da) 2002-04-15
EP0663912B1 (en) 2001-12-12
WO1994008992A1 (en) 1994-04-28
ES2169727T3 (es) 2002-07-16
EP0663912A4 (en) 1995-02-17
PT663912E (pt) 2002-06-28
IL107184A0 (en) 1994-01-25
CA2136075C (en) 2004-12-14
JP3098035B2 (ja) 2000-10-10
AU687017B2 (en) 1998-02-19
CA2136075A1 (en) 1994-04-28
DE69331329D1 (de) 2002-01-24
KR950701920A (ko) 1995-05-17
ATE210656T1 (de) 2001-12-15
DE69331329T2 (de) 2002-08-08
JPH08502481A (ja) 1996-03-19
KR100311546B1 (ko) 2005-12-06
EP0663912A1 (en) 1995-07-26

Similar Documents

Publication Publication Date Title
IL107184A (en) Heterocyclic ether compounds that enhance cognitive function
AP1852A (en) '3-Azabicyclo{3.1.0] hexane derivatives as opiate receptors ligands.
TW264477B (xx)
NZ227131A (en) Compositions for improving cognitive function by administering 1,2-oxazole derivatives
NZ330023A (en) Fused pyrrolecarboxanilides and their use as a GABA brain receptor ligands
FI931888A (fi) Kramploesande cykliska fruktopyranossulfiter -och sulfater
HK1012341A1 (en) Pyrrolocarbazole
AP2000001846A0 (en) Triazine compounds for treatment of CNS disorders.
MY125674A (en) Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis
MX9702259A (es) Derivados de quinoxalina utiles en terapia.
DE3475073D1 (en) Azahomoerythromycin b derivatives and intermediates thereof
PT1049672E (pt) Derivados de azetidinocarboxamida para o tratamento de disturbios do snc
AU2178199A (en) Azetidinecarboxamide derivatives for the treatment of cns disorders
GR3022217T3 (en) Treatment of cataract with prostacyclin compounds
PT1049670E (pt) Derivados de azetidinocarboxamida para o tratamento de perturbacoes do snc
GR3023827T3 (en) Indole-sulfonamides as antitumor agents.
ES2004215A6 (es) Procedimiento para preparar quinazolinas tetraciclicas
FI933652A (fi) Foerfarande foer framstaellning av 1-osubstituerade 3-aminopyrroler

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees